Wenger Plattner has advised Bio-Techne Corporation on the acquisition of Lunaphore Inc.
A Wenger Plattner team led by Oliver Künzler has advised NASDAQ-listed Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, on all legal and tax aspects regarding the acquisition of Lunaphore, Inc.
The further core team consisted of Markus Muehlemann, Benjamin Dürig, Suzanne Eckert, Martina Braun, Cristina Solo de Zaldívar, Sarah Hilber, André S. Berne, Valérie Berger, Linda Lauterbach
Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024.
Founded in 2014 and headquartered in Tolochenaz, Switzerland, Lunaphore is a leading developer of fully automated spatial biology solutions using precision microfluidic technology capable of revealing hyperplex proteomic and transcriptomic biomarkers in tumors and other tissues at single-cell and subcellular resolution.
Congratulations to all parties!